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Abstract 
Acute myeloid leukemia (AML) is a clonal heterogeneous disease of the mye-
loid white blood cells. It is characterised by an accumulation of immature 
blast cells and a number of chromosomal and genetic mutations have been 
identified. In both de novo and therapy-related AML, defective DNA repair 
mechanisms are responsible for some of these genetic abnormalities. Target-
ing the DNA repair mechanism has been shown to be successful against cer-
tain forms of solid tumors and may represent a novel therapeutic approach 
for AML. 
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1. Introduction 
Acute Myeloid Leukemia (AML) is a progressive disease of the myeloid blood 
line of hematopoietic cells [1]. A rapid growth of undifferentiated white blood 
cells is seen in AML, which causes a reduction in the number of mature and 
functioning red blood cells, white blood cells and platelets. AML is most com-
monly seen in people over the age of 65 but it can be seen in younger patients 
[2]. Although AML is caused by cytogenetic and genetic mutations [3], there are 
some rare inherited conditions, such as Fanconi Anemia, Bloom Syndrome and 
Downs Syndrome, which confer an increasing risk of developing a hematological 
malignancy [4]. 
Chromosomal translocations are a regular occurrence in AML. The prognosis 
of AML with chromosomal translocations is governed by the translocated genes 
involved [5]. The most common breakpoints happen in genes with highly im-
portant cellular functions such as the PML (ProMyelocytic Leukemia), RARA 
(Retinoic Acid Receptor alpha), TEL (also known at ETV6 (ETS family tran-
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scription factor variant 6)), MLL (Mixed Lineage Leukemia), ETO (Eight Twen-
ty-Two, also known as RUNX1T1 (RUNX1 Translocation Partner 1)), BCR 
(Breakpoint Cluster Region), HOXA9 (Homeobox A9) and ABL1 (ABL Proto- 
Oncogene 1) [5]. The fusion proteins (such as PML-RARA), created through 
numerous chromosomal translocations, block differentiation, which leads to 
abnormal blood cell phenotypes. Ineffective or incomplete DNA repair mechan-
isms are responsible for the formation of chromosomal translocations. Targeting 
the DNA repair pathway as a form of treatment is relatively new, and although it 
has been shown to be successful against certain forms of solid tumors, it has 
been used infrequently in leukemia [6]. 
2. Therapy-Related AML 
The occurrence of AML can be de novo; however, a number of AML cases are 
therapy-related [7]. As the overall-survival rate of many cancers is increasing, so 
too is the number of living people who have received cytotoxic treatments. These 
people are at risk of developing secondary neoplasms, particularly haematologi-
cal neoplasms. As a result of this, a rise in the frequency of patients presenting 
with therapy-related AML (t-AML) can be seen [7]. T-AML is categorised as any 
AML occurring in patients which have previously received cytotoxic drug treat-
ments or radiotherapy which targeted active bone marrow sites [8]. These agents 
are capable of heavily mutating DNA and causing gross chromosomal rear-
rangements. Additionally DNA-repair pathways are often disrupted which leads 
to a build-up in cells with abnormally repaired / mutated DNA [9] [10].  
3. DNA Repair Pathways 
DNA repair mechanisms play an important role in the maintenance of healthy 
cells. Lack of sufficient repair mechanisms causes DNA damage which can lead 
to apoptosis, cell cycle arrest or even cancer [11]. DNA repair genes do not only 
confer a negative effect by loss of function mutations. Overexpression of DNA 
repair genes encourages cells to try and repair severe damage instead of under-
going apoptosis. This allows damaged cells to become resistant to chemotherapy 
and even targeted therapies [12]. As a result of sub-par DNA repairing, disease 
progression worsens due to the build-up of genomic mistakes. Moreover, in-
creased expression levels of BRCA1, RAD51 and CHK2, among other DDR 
genes, are associated with a poor prognosis [12] [13]. Thus there is a growing of 
evidence to show the role played by DNA repair pathways in cancer prevention. 
Identifying differences between cancerous cells and non-cancerous cells is a key 
element in the production of targeted therapies. There are at least 6 with three 
major DNA repair pathways in human cells, each playing a different role in 
DNA maintenance (Figure 1): Base excision repair (BER); nucleotide excision 
repair (NER); mismatch repair (MMR); homologous recombination; Fanconi 
anemia/BRCA pathway (HR); non-homologous end-joining (NHEJ) and trans- 
lesion DNA synthesis (TLS) [11]. Due to the multitude of DNA repair mechan-
isms, a defect in one pathway does not necessarily lead to cell death. In fact, a 
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defect often leads to a damaged cell that will continue to grow and multiply with 
this defect creating a mass of cells imperfectly replicated. Double stranded 
breaks present serious problems for cells as they can cause major changes in se-
quence and even chromosome rearrangements (Figure 2). There are two major 
mechanisms for repairing double stranded breaks-homologous repair and non- 
homologous end joining [14].  
3.1. Homologous Recombination 
Homologous recombination (HR) is the more complex, but also the most accu-
rate, of the two methods. HR is initiated by sensing of the DSB by at the Ataxia 
Telangiectasia Mutated (ATM) Kinase which promotes the 5' - 3' resection of the 
broken strands, through recruitment and activation of the Mre11:Rad50:Nbs1 
(MRN) complex (Mre11 harbours both exo- and endo-nuclease activity), result-
ing in a pair of single stranded 3’ overhangs which recruit proteins to aid in the 
repair process (15). RPA is the first protein to bind to these 3’ ends helping to 
stabilise and protect these single stranded DNA regions. The recombinase pro- 
 
 
Figure 1. Three commonly used pathways in the repair of both single and double strand 
breaks. 
 
 
Figure 2. Schematic showing how topoisomerase has the potential to lead to chromo-
somal translocation via inefficient DNA repair. 
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tein Rad51 then replaces RPA, a process driven by several mediating proteins— 
such as the BRCA1 and BRAC2. Rad51 stimulates repair by catalysing the inva-
sion of the sister strand and aligning the single stranded 3’ overhang with its 
complementary region within the sister chromatid. This results in the forma-
tion of two replication fork like structures (known as a Holiday Junction), al-
lowing the resected DNA to be replaced by the DNA replication machinery us-
ing the undamaged sister chromatid as a template [15] [16]. Although, the most 
accurate DSB repair pathway, as it relies on the presence of an intact sister 
chromatid, HR can only occur during S or G2 phases of the cell cycle. The cor-
rect balance of Rad51 and RPA proteins are crucial for efficient and successful 
HR mediated repair. Indeed, Rad51 overexpression has been observed in many 
cancer types including in breast cancer and in several sub-types of leukemia 
[16] [17]. 
As the HR repair pathway is so important in cell survival and correct replica-
tion, it has become a therapeutic target in cancer cells which already contain a 
DNA repair defects. Molecules which inhibit HR activity, such as Mirin, are in 
the early phases of development [18]. Mirin inhibits the nuclease activity of 
Mre11 within the MRN complex, thereby inhibiting the initiation of HR. These 
small molecule inhibitors, and others similar (such as RAD51 inhibitors), are 
still in early phase trials. These molecules target HR through various avenues 
[18]. Targeting cABL and HSP90 are also being investigated in HRR deficient 
cells [16].  
3.2. Non-Homologous End Joining 
Non-homologous end joining is a much quicker and simpler mechanism for 
DSB repair. During NHEJ, the two DNA strands are re-joined even if they do 
not have sequence homology.  Interestingly, NHEJ activity has been shown to 
be increased in chronic myeloid leukemia [19]. However, defects are seen often 
in lymphoid malignancies [20] [21]. Over activity of NHEJ is seen in many can-
cers, likely due to the high level of DNA damage found in cancers and/or 
through compensation due to HR defects in these cells. As NHEJ and HR are the 
only DSB repair pathways, loss of both pathways would likely to result in syn-
thetic lethality in cancer cells. As discussed earlier, there are already a number of 
HR targeted therapies in early phase trials, which may be of benefit in tumours 
with NHEJ defects. However, the more common defect observed in cancer are 
HR defects, which result in NHEJ, the error prone DSB repair pathway becom-
ing the predominant repair pathway in these cells (and thus leading to a more 
mutagenic (phenotype). Thus it is likely that NHEJ inhibitors may be more 
promising as cancer therapeutics. The subunit of DNA-PKCs is a promising 
target for inhibition as it plays an important role in NHEJ and is shown to confer 
radio-resistance in a number cancer types when overexpressed. Although 
Wortmannin was the first drug synthesised to target NHEJ, many more specific 
agents have since been developed, with some entering phase I and phase II trials 
[14] [21].  
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4. DNA Repair Pathway Inhibitors 
4.1. PARP 1 Inhibitors 
The Poly (ADP-ribose) polymerase, PARP, gene encodes a 1014 AA protein that 
is involved in many cellular processes, including cell cycle regulation and apop-
tosis [21] [22]. One of PARP most important functions, however, is in the DNA 
damage response. PARP is active in the repair of both single stranded and 
double stranded DNA breaks with PARPs playing a major role in the BER (re-
sponsible for the repair of single strand breaks and modified/damaged bases) 
and the NHEJ pathways [21]. 
The PARP family of enzymes catalyse the movement of ADP-ribose from the 
NAD+ (nicotinamide adenine dinucleotide) subunit onto target proteins. PARP1 
is recognised as the most important of the PARP family proteins [23] [24]. 
PARP1 generates a long strand of poly (ADP-ribose) which can covalently attach 
to target proteins assisting DNA repair as well as other cellular processes [25]. 
When PARP1 is inhibited, BER loses its ability to repair SSBs. These breaks sub-
sequently evolve into DSBs during replication. This results in an overwhelming 
amount of damage for the cells to deal with particularly in the background of an 
already depleted DSB repair system [16]. Apoptosis generally follows soon after 
as the genetic mutations reach a lethal level. The idea of synthetic lethality was 
introduced to target cells that already contain an intrinsic repair pathway defect. 
While one defect is not generally detrimental to a cells survival, the synthetic in-
troduction of another pathway defect can be enough to push a cell into such dis-
array that the only option it faces is apoptosis [23].  
As homologous recombination repair deficient cells are so dependent on the 
BER pathway, in which PARP1 plays a key role, targeting PARP1, is seen as an 
effective method of targeting these cells [21] [23]. Additionally, some biomark-
ers now highlight any defects in DNA repair mechanisms. Indeed, the levels of 
PARP1 itself may act as a biomarker with over-active PARP1 activity suggest 
that the tumour or leukemia may be responsive to PARP inhibition. Mutated 
BRCA is the most recognised and reliable biomarker for DNA repair deficiency 
but many others, including CDK12 and FA proteins, are also used in repair defi-
ciency analysis [26].  
DNA repair inhibitors have the unique ability to target cancerous cells while 
leaving normal cells unharmed. Despite the clear logic behind the use of PARP 
inhibitors (PARPi) in DNA repair deficient tumours, the development of early 
PARPi were not as successful in the clinic. The initial PARP1 inhibitor created, 
Iniparib, was unsuccessful in a phase III trial when used as a treatment for 
triple-negative breast cancer [26]. It also proved to be ineffective in a phase II 
non-small lung cancer trial. Indeed, the selectivity of Iniparib was low, as was its 
ability to efficiently inhibit PARP1. PARPi designed to confer a stronger affinity 
for PARP1 and a greater rate of inhibition. Despite early clinical trial doubts, one 
such inhibitor Olaparib has had very positive results in the treatment of 
BRCA-deficient ovarian cancer and in unfavorable AML [27]. More recently, the 
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use of Olaparib has been approved as a treatment option for prostate cancer with 
either a BRCA or ATM mutation [26]. A further nine PARP1 inhibitors are cur-
rently in different stages of clinical trials, amongst which Rucaparib and Talazo-
parib have shown promising results [26].  
4.2. Other DNA Repair Pathway Inhibitors 
Targeting DNA repair pathways is relatively new in the field of AML yet inter-
esting results seen in other tumor types suggest a promising future in this area of 
AML therapeutics. 
Although PARP inhibitors have been heavily focused on in recently, there are 
many aspects of DNA repair system that may be targeted for future cancer treat- 
ments.  
As previously stated, the overexpression of repair pathway components such 
as DNA-PKCs and BRCA-1 can also confer a negative impact [13]. Recent stu-
dies have identified an up regulation of similar elements in chemotherapy resis-
tant AML cell lines. Indeed Nishida et al showed that DNA-PKCs and DNA Li-
gase IV are up-regulated in K562 and HL60 cells which are resistant to daunoru-
bicin; whilst knocking down DNA-PKC’s in these cells induces sensitivity to 
daunorubicin [28]. 
DNA repair inhibitors need not be used as single agents. By combining them 
with therapies which target other mutations they insure the cell has no back-up 
pathway to depend on. For example, PARPi can be used in conjunction with 
Temozolomide to inhibit the use of the BER pathway which is often utilised by 
Temolozolomide-resistant cells [27]. 
5. Conclusion 
Although AML is clearly a disease of immense heterogeneity particularly with 
respect to the distinct genetic mutations found in this disease. However, it is 
through targeting these disparities directly that effective treatments are likely to 
be found. The targeting of DNA repair deficiency is an area of unmet clinical 
need in AML. Few people have derived links between genetic mutations in AML 
and possible targets for repair pathway inhibitors. Based on promising results in 
other cancer types, it is likely to be an emerging area of research in AML as well 
as other hematological malignancies.  
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